又一未盈利生物科技公司科济药业控股有限公司（科济药业）披露招股书，预计于6月18日在港上市。环球律师事务所、达维律师事务所担任发行人律师；史密夫斐尔律师事务所、中伦律师事务所则为联席保荐人提供法律意见。
科济药业上市募资额为31亿港元，是2021年迄今最大的18A公司IPO。
科济药业成立于2014年，是一家在中国及美国拥有业务的生物制药公司，专注于治疗血液恶性肿瘤和实体瘤的创新CAR-T细胞疗法。
迈普达律师事务所担任科济药业的离岸律师；高盛、瑞银为其联席保荐人。
达维团队牵头律师为合伙人何鲤、褚洋；史密夫斐尔团队牵头律师为合伙人艾迈修、谢守德。
Davis Polk, HSF lead on CARsgen’s planned $400 mln HK IPO
Davis Polk & Wardwell and Global Law Office are advising medical research firm CARsgen Therapeutics on its planned IPO in Hong Kong, with Herbert Smith Freehills and Zhong Lun Law Firm advising the joint underwriters. The IPO is expected to raise up to $400 million.
CARsgen is a biopharmaceutical company established in 2014, with operations in China and the U.S. It focuses on CAR-T cell therapies for the treatment of hematological malignancies and solid tumors.
Maples and Calder is providing the issuer offshore legal advice. The joint underwriters are Goldman Sachs and UBS.
The Davis Polk team was led by partners He Li, Chu Yang, while the HSF team was led by partners Matt Emsley, Stanley Xie.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
